Home > Healthcare > Pharmaceuticals > Finished Drug Form > Vaginitis Therapeutics Market

Vaginitis Therapeutics Market Size

Report ID: GMI7213
Published Date: Oct 2023
Report Format: PDF

Download Free Sample

Vaginal Therapeutics Market Size

Vaginitis Therapeutics Market size was around USD 3.6 billion in 2022 and is expected to reach USD 7.3 billion by 2032 with a CAGR of 7.6%. High prevalence of vaginal infections, growing awareness pertaining to women’s health and the availability of effective treatments, and various government and private initiatives are driving the demand.

To get key market trends

Download Free Sample

For instance, the National Institute of Allergy and Infectious Diseases (NIAID) funded scientists to develop a test for yeast infection to provide appropriate anti-fungal treatment in infected females. Thus, government-sponsored health programs often provide subsidized or free healthcare services, including diagnosis and treatment for vaginal infections, resulting to growing access for affected individuals. Further, the rising awareness about feminine hygiene, self-medication, easy of availability of over the counter drugs such as creams and gels is expected to foster the market trends.

Vaginitis Therapeutics Market Report Attributes
Report Attribute	Details
Base Year:	2022
Vaginitis Therapeutics Market Size in 2022:	USD 3.6 Billion
Forecast Period:	2023 to 2032
Forecast Period 2023 to 2032 CAGR:	7.6 %
2032 Value Projection:	USD 7.3 Billion
Historical Data for:	2018 to 2022
No. of Pages:	170
Tables, Charts & Figures:	316
Segments covered:	Disease Type, Drug Class, Route of Administration, Mode, Distribution Channel, and Region
Growth Drivers:	High prevalence of vaginal infections Growing awareness about womens health and the availability of effective treatments Advancements in drug development
Pitfalls & Challenges:	Growing antibiotic resistance

Learn more about the key segments shaping this market

Download Free Sample

Vaginitis therapeutics refer to the medical interventions and treatments used to manage and alleviate the symptoms of vaginitis, a common medical condition characterized by inflammation or irritation of the vagina. Vaginitis can be caused by various factors, including infections, hormonal imbalances, or irritants, and the choice of treatment depends on the underlying cause.

Authors: Mariam Faizullabhoy , Gauri Wani

Frequently Asked Questions (FAQ) :

Vaginitis therapeutics industry size was USD 3.6 billion in 2022 and is expected to reach USD 7.3 billion by 2032 due to the rising prevalence of vaginal infections, growing awareness pertaining to women’s health and the increasing availability of effective treatments worldwide.

The bacterial vaginosis disease type segment held 43.6% share of the vaginitis therapeutics industry in 2022 and is expected to register a significant CAGR from 2023-2032 on account of it being the most prevalent vaginal infection among women of reproductive age.

North America vaginitis therapeutics industry is expected to grow at 7.3% CAGR from 2023-2032 owing to a high prevalence of menopausal and postmenopausal women in the region.

Pfizer, Inc., Merck & Co., Novartis AG, Bayer AG, Lupin Pharmaceuticals, Inc., Sanofi SA, Dr. Reddy’s Laboratories Ltd, Sun Pharmaceuticals Pvt Ltd, Cipla Ltd, and Takeda Pharmaceuticals, are some of the major market worldwide.